- Home
- OM vs GUTS Comparison
OM vs GUTS Comparison
Compare OM & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- GUTS
- Stock Information
- Founded
- OM 2003
- GUTS 2010
- Country
- OM United States
- GUTS United States
- Employees
- OM 354
- GUTS N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GUTS
- Sector
- OM Health Care
- GUTS
- Exchange
- OM Nasdaq
- GUTS NYSE
- Market Cap
- OM 305.5M
- GUTS 58.8M
- IPO Year
- OM 2020
- GUTS 2024
- Fundamental
- Price
- OM $19.51
- GUTS $2.10
- Analyst Decision
- OM Buy
- GUTS Buy
- Analyst Count
- OM 2
- GUTS 1
- Target Price
- OM $29.50
- GUTS $10.00
- AVG Volume (30 Days)
- OM 221.8K
- GUTS 244.2K
- Earning Date
- OM 05-07-2025
- GUTS 05-13-2025
- Dividend Yield
- OM N/A
- GUTS N/A
- EPS Growth
- OM N/A
- GUTS N/A
- EPS
- OM N/A
- GUTS N/A
- Revenue
- OM $115,273,000.00
- GUTS $60,000.00
- Revenue This Year
- OM $10.42
- GUTS N/A
- Revenue Next Year
- OM $11.65
- GUTS N/A
- P/E Ratio
- OM N/A
- GUTS N/A
- Revenue Growth
- OM N/A
- GUTS N/A
- 52 Week Low
- OM $5.85
- GUTS $0.87
- 52 Week High
- OM $78.30
- GUTS $7.89
- Technical
- Relative Strength Index (RSI)
- OM 77.59
- GUTS 71.21
- Support Level
- OM $14.80
- GUTS $1.51
- Resistance Level
- OM $12.79
- GUTS $1.79
- Average True Range (ATR)
- OM 1.60
- GUTS 0.20
- MACD
- OM 0.81
- GUTS 0.06
- Stochastic Oscillator
- OM 96.95
- GUTS 93.64
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.